216 related articles for article (PubMed ID: 35484662)
41. Lights and Shade of Next-Generation Pi3k Inhibitors in Chronic Lymphocytic Leukemia.
Visentin A; Frezzato F; Severin F; Imbergamo S; Pravato S; Romano Gargarella L; Manni S; Pizzo S; Ruggieri E; Facco M; Brunati AM; Semenzato G; Piazza F; Trentin L
Onco Targets Ther; 2020; 13():9679-9688. PubMed ID: 33061448
[TBL] [Abstract][Full Text] [Related]
42. The PI3K p110δ Isoform Inhibitor Idelalisib Preferentially Inhibits Human Regulatory T Cell Function.
Chellappa S; Kushekhar K; Munthe LA; Tjønnfjord GE; Aandahl EM; Okkenhaug K; Taskén K
J Immunol; 2019 Mar; 202(5):1397-1405. PubMed ID: 30692213
[TBL] [Abstract][Full Text] [Related]
43. Clinical use of PI3K inhibitors in B-cell lymphoid malignancies: today and tomorrow.
Greenwell IB; Flowers CR; Blum KA; Cohen JB
Expert Rev Anticancer Ther; 2017 Mar; 17(3):271-279. PubMed ID: 28112970
[TBL] [Abstract][Full Text] [Related]
44. BCR pathway inhibition as therapy for chronic lymphocytic leukemia and lymphoplasmacytic lymphoma.
Wiestner A
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):125-34. PubMed ID: 25696845
[TBL] [Abstract][Full Text] [Related]
45. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.
Hock BD; MacPherson SA; McKenzie JL
PLoS One; 2017; 12(3):e0172858. PubMed ID: 28257435
[TBL] [Abstract][Full Text] [Related]
46. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
Barrientos JC
Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
[TBL] [Abstract][Full Text] [Related]
47. Idelalisib for optimized CD19-specific chimeric antigen receptor T cells in chronic lymphocytic leukemia patients.
Stock S; Übelhart R; Schubert ML; Fan F; He B; Hoffmann JM; Wang L; Wang S; Gong W; Neuber B; Hückelhoven-Krauss A; Gern U; Christ C; Hexel M; Schmitt A; Schmidt P; Krauss J; Jäger D; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2019 Sep; 145(5):1312-1324. PubMed ID: 30737788
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of idelalisib for the treatment of indolent B-cell malignancies.
Smolewski P; Rydygier D
Expert Opin Pharmacother; 2020 Oct; 21(15):1915-1926. PubMed ID: 32686971
[TBL] [Abstract][Full Text] [Related]
49. Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches.
Nakamura S; Ponzoni M
Pathology; 2020 Jan; 52(1):15-29. PubMed ID: 31757436
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical analysis of the novel marginal zone B-cell marker IRTA1 in malignant lymphoma.
Ikeda JI; Kohara M; Tsuruta Y; Nojima S; Tahara S; Ohshima K; Kurashige M; Wada N; Morii E
Hum Pathol; 2017 Jan; 59():70-79. PubMed ID: 27666766
[TBL] [Abstract][Full Text] [Related]
51. PI3Kδ inhibition modulates regulatory and effector T-cell differentiation and function in chronic lymphocytic leukemia.
Hanna BS; Roessner PM; Scheffold A; Jebaraj BMC; Demerdash Y; Öztürk S; Lichter P; Stilgenbauer S; Seiffert M
Leukemia; 2019 Jun; 33(6):1427-1438. PubMed ID: 30573773
[TBL] [Abstract][Full Text] [Related]
52. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies.
Deng C; Lipstein MR; Scotto L; Jirau Serrano XO; Mangone MA; Li S; Vendome J; Hao Y; Xu X; Deng SX; Realubit RB; Tatonetti NP; Karan C; Lentzsch S; Fruman DA; Honig B; Landry DW; O'Connor OA
Blood; 2017 Jan; 129(1):88-99. PubMed ID: 27784673
[TBL] [Abstract][Full Text] [Related]
53. Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.
Kojima M; Sato E; Oshimi K; Murase T; Koike T; Tsunoda S; Matsumoto T; Marutsuka K; Ogiya D; Moriuchi M; Tokunaka M; Yara Kikuti Y; Kikuchi T; Nakamura N; Ando K
J Clin Exp Hematop; 2010; 50(2):107-12. PubMed ID: 21123968
[TBL] [Abstract][Full Text] [Related]
54. PI3K signaling pathway in normal B cells and indolent B-cell malignancies.
Pongas G; Cheson BD
Semin Oncol; 2016 Dec; 43(6):647-654. PubMed ID: 28061982
[TBL] [Abstract][Full Text] [Related]
55. Chemotherapy-Free Management of Follicular and Marginal Zone Lymphoma.
Ollila TA; Olszewski AJ
Cancer Manag Res; 2021; 13():3935-3952. PubMed ID: 34017197
[TBL] [Abstract][Full Text] [Related]
56. Idelalisib Rescues Natural Killer Cells from Monocyte-Induced Immunosuppression by Inhibiting NOX2-Derived Reactive Oxygen Species.
Akhiani AA; Hallner A; Kiffin R; Aydin E; Werlenius O; Aurelius J; Martner A; Thorén FB; Hellstrand K
Cancer Immunol Res; 2020 Dec; 8(12):1532-1541. PubMed ID: 32967913
[TBL] [Abstract][Full Text] [Related]
57. Clinical presentation and management of marginal zone lymphomas.
Thieblemont C
Hematology Am Soc Hematol Educ Program; 2005; ():307-13. PubMed ID: 16304396
[TBL] [Abstract][Full Text] [Related]
58. Cutaneous lymphoid hyperplasia and cutaneous marginal zone lymphoma: comparison of morphologic and immunophenotypic features.
Baldassano MF; Bailey EM; Ferry JA; Harris NL; Duncan LM
Am J Surg Pathol; 1999 Jan; 23(1):88-96. PubMed ID: 9888708
[TBL] [Abstract][Full Text] [Related]
59. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Gopal AK; Kahl BS; de Vos S; Wagner-Johnston ND; Schuster SJ; Jurczak WJ; Flinn IW; Flowers CR; Martin P; Viardot A; Blum KA; Goy AH; Davies AJ; Zinzani PL; Dreyling M; Johnson D; Miller LL; Holes L; Li D; Dansey RD; Godfrey WR; Salles GA
N Engl J Med; 2014 Mar; 370(11):1008-18. PubMed ID: 24450858
[TBL] [Abstract][Full Text] [Related]
60. Expression and function of phosphoinositide 3-kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow.
Ali AY; Guan Q; Wu X; Hou S; Banerji V; Johnston JB; Wall D; Szwajcer D; Gibson SB; Marshall AJ
Br J Haematol; 2019 Jun; 185(5):883-887. PubMed ID: 30873593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
